Arena Pharmaceuticals (ARNA) 4.51 $ARNA Will Ar
Post# of 64074
Posted On: 02/28/2015 7:28:08 PM
Arena Pharmaceuticals (ARNA) 4.51 $ARNA
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 3:22PM CST
Arena Pharmaceuticals (ARNA) is scheduled to report fourth-quarter 2014 results on Mar 2.
AMRN: 1.51 (+0.05), PETX: 19.26 (+0.03), ARNA: 4.51 (-0.24)
Arena's Belviq Prescriptions Hold Up During Presidents' Day Holiday Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 27, 1:58PM CST
ARNA: 4.51 (-0.24)
Lessons From A Dozen Years Of Short Selling
Whitney Tilson - Seeking Alpha - Fri Feb 27, 9:39AM CST
(Editor's Note: Long-time contributor Whitney Tilson developed a presentation titled "Lessons from a Dozen Years of Short Selling" that he's presented at a handful of investment conferences in New York City. With his permission, we're now...
MBI: 9.00 (-0.04), FCEL: 1.31 (+0.06), HLF: 31.01 (-3.81), AFC: 25.59 (+0.14), VJET: 8.91 (+0.05), LL: 51.86 (+2.63), BLDP: 2.29 (-0.07), NSR: 26.52 (-0.14), TXTR: 28.21 (-0.48), RPTP: 9.27 (-0.37), LNKD: 267.20 (-3.56), ONVO: 5.92 (-0.14), XONE: 15.13 (-0.40), ARNA: 4.51 (-0.24), AGM: 31.94 (+0.35), PLUG: 3.08 (-0.03), FB: 78.97 (-1.44), DDD: 30.47 (+0.41), DECK: 74.24 (+0.50), TRIP: 89.25 (-0.61), CSLT: 7.29 (-0.21), LRN: 16.93 (unch), PCLN: 1,237.48 (-3.77), NFLX: 474.91 (-8.12), CROX: 11.15 (+0.46), CALL: 7.72 (+0.18), WRLD: 82.11 (-1.09), SODA: 17.92 (+0.66)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.94 (-0.30), CASM: 1.29 (+0.02), AMRN: 1.51 (+0.05), XON: 41.06 (-1.86), OSIR: 17.27 (-0.07), CPIX: 6.13 (+0.24), AMED: 30.17 (-0.73), CTIC: 2.34 (-0.04), INSY: 60.06 (-0.65), ECYT: 5.80 (-0.11), CMRX: 40.48 (-0.60), KYTH: 41.55 (-1.69), TRIB: 17.76 (-0.21), GALE: 1.80 (-0.03), ARNA: 4.51 (-0.24), XLRN: 40.63 (-0.37), ACRX: 8.86 (-0.10), ENDP: 85.60 (+0.36), DPLO: 30.00 (-0.09), SLXP: 157.20 (+0.25), PPHM: 1.41 (+0.03), MYL: 57.33 (+0.09), CBPO: 76.60 (-0.31), RGEN: 25.71 (-0.49), HALO: 15.07 (-0.21), ALIM: 5.23 (-0.05), ACHN: 12.14 (-0.35), GERN: 3.02 (-0.13), DARA: 0.99 (+0.05), SCMP: 15.38 (-0.62), ICPT: 221.37 (+2.30), CDXS: 3.53 (-0.02), PCRX: 114.77 (-1.22), PBYI: 213.01 (+7.05), FOLD: 8.76 (-0.03)
Orexigen's Q4 Results Disappoint, But Contrave Is Gaining Market Share
Kanak Kanti De - at Seeking Alpha - Thu Feb 26, 3:39PM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch
Brian Orelli, The Motley Fool - Motley Fool - Thu Feb 26, 6:02AM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave was nothing to get too excited about. In the fourth quarter, which included 10 weeks of the launch, net sales of the drug were just $6.5 million, which resulted in $1.3 million in...
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena: Belviq Television Ads Resume After 1 Week Hiatus
Spencer Osborne - at Seeking Alpha - Tue Feb 24, 7:11AM CST
OREX: 5.64 (-0.23), ARNA: 4.51 (-0.24)
Orexigen: Contrave Scripts Pass 9,000 - Closing In On Qsymia
Spencer Osborne - at Seeking Alpha - Mon Feb 23, 10:00AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena: Belviq Sales Show Modest Gain - Time To Assess 2015 Expectations?
Spencer Osborne - at Seeking Alpha - Mon Feb 23, 9:33AM CST
OREX: 5.64 (-0.23), NVO: 47.75 (+0.22), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena's Belviq Slows At A Bad Time
Clinically Sound Investor - at Seeking Alpha - Mon Feb 23, 8:57AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus
at The Street - Fri Feb 20, 2:47PM CST
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 0.94 (unch), AMRN: 1.51 (+0.05), HWAY: 22.38 (-0.37), HLS: 43.46 (-0.62), CYBX: 68.50 (+1.90), ESRX: 84.79 (+0.25), ECYT: 5.80 (-0.11), DXCM: 60.74 (-1.22), NSTG: 10.51 (-0.08), SRPT: 13.90 (+0.08), HZNP: 20.53 (+1.46), MDXG: 10.35 (-0.13), DEPO: 21.95 (-0.65), ANIK: 39.92 (-0.04), NKTR: 13.07 (+0.09), KERX: 12.16 (+0.23), ALIM: 5.23 (-0.05), EPZM: 23.52 (-0.08), AEGR: 27.20 (+0.20), MDRX: 12.01 (-0.74), ELGX: 15.77 (+0.09), NUVA: 45.75 (+0.76), HPTX: 29.55 (+1.82), GNMK: 12.71 (-0.19), MDVN: 117.53 (-2.21), HBIO: 5.46 (-0.09), ACAD: 37.97 (+0.19), ST: 53.74 (+0.09), RPTP: 9.27 (-0.37), FMI: 47.76 (-0.58), GMED: 24.28 (-0.78), JAZZ: 170.09 (-5.10), PTCT: 71.33 (-2.13), INFI: 15.20 (-0.84), ARNA: 4.51 (-0.24), EXEL: 2.93 (unch), NEO: 4.54 (+0.13), EXAS: 22.47 (-0.89), ALKS: 70.25 (-0.98), HTWR: 85.23 (-1.15), MNKD: 6.52 (-0.30), IPXL: 40.29 (-0.41), SQNM: 3.50 (-0.02), HALO: 15.07 (-0.21), ISIS: 68.56 (+1.23), CLVS: 76.46 (-1.43), BIO: 127.18 (+8.18), BIOS: 6.11 (+0.19), PCRX: 114.77 (-1.22)
Orexigen's Contrave Sales Recover - Investors Should Look To Europe
Spencer Osborne - at Seeking Alpha - Wed Feb 18, 11:02AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena's Belviq Scripts Spike - Maintaining This Trajectory Important
Spencer Osborne - at Seeking Alpha - Wed Feb 18, 8:22AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference
PR Newswire - Wed Feb 18, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 2015 RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The New York Palace Hotel in New York City.
ARNA: 4.51 (-0.24)
Vivus' Qsymia Experiencing Both Prescription Growth And Market Share Erosion
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:03PM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Orexigen's Contrave Resumes Solid Growth Rate
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:45AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena's Belviq Hits New High Prescription Mark, But Needs Similar Future Growth
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:42AM CST
ARNA: 4.51 (-0.24)
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 102.51 (-0.29), OREX: 5.64 (-0.23), ECYT: 5.80 (-0.11), NVO: 47.75 (+0.22), MRK: 58.54 (-0.42), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.64 (-0.23), VRTX: 119.43 (-0.54), NVO: 47.75 (+0.22), VVUS: 2.61 (-0.08), QSII: 17.38 (-0.04), MDRX: 12.01 (-0.74), ARNA: 4.51 (-0.24)
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 3:22PM CST
Arena Pharmaceuticals (ARNA) is scheduled to report fourth-quarter 2014 results on Mar 2.
AMRN: 1.51 (+0.05), PETX: 19.26 (+0.03), ARNA: 4.51 (-0.24)
Arena's Belviq Prescriptions Hold Up During Presidents' Day Holiday Week
Clinically Sound Investor - at Seeking Alpha - Fri Feb 27, 1:58PM CST
ARNA: 4.51 (-0.24)
Lessons From A Dozen Years Of Short Selling
Whitney Tilson - Seeking Alpha - Fri Feb 27, 9:39AM CST
(Editor's Note: Long-time contributor Whitney Tilson developed a presentation titled "Lessons from a Dozen Years of Short Selling" that he's presented at a handful of investment conferences in New York City. With his permission, we're now...
MBI: 9.00 (-0.04), FCEL: 1.31 (+0.06), HLF: 31.01 (-3.81), AFC: 25.59 (+0.14), VJET: 8.91 (+0.05), LL: 51.86 (+2.63), BLDP: 2.29 (-0.07), NSR: 26.52 (-0.14), TXTR: 28.21 (-0.48), RPTP: 9.27 (-0.37), LNKD: 267.20 (-3.56), ONVO: 5.92 (-0.14), XONE: 15.13 (-0.40), ARNA: 4.51 (-0.24), AGM: 31.94 (+0.35), PLUG: 3.08 (-0.03), FB: 78.97 (-1.44), DDD: 30.47 (+0.41), DECK: 74.24 (+0.50), TRIP: 89.25 (-0.61), CSLT: 7.29 (-0.21), LRN: 16.93 (unch), PCLN: 1,237.48 (-3.77), NFLX: 474.91 (-8.12), CROX: 11.15 (+0.46), CALL: 7.72 (+0.18), WRLD: 82.11 (-1.09), SODA: 17.92 (+0.66)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 34.94 (-0.30), CASM: 1.29 (+0.02), AMRN: 1.51 (+0.05), XON: 41.06 (-1.86), OSIR: 17.27 (-0.07), CPIX: 6.13 (+0.24), AMED: 30.17 (-0.73), CTIC: 2.34 (-0.04), INSY: 60.06 (-0.65), ECYT: 5.80 (-0.11), CMRX: 40.48 (-0.60), KYTH: 41.55 (-1.69), TRIB: 17.76 (-0.21), GALE: 1.80 (-0.03), ARNA: 4.51 (-0.24), XLRN: 40.63 (-0.37), ACRX: 8.86 (-0.10), ENDP: 85.60 (+0.36), DPLO: 30.00 (-0.09), SLXP: 157.20 (+0.25), PPHM: 1.41 (+0.03), MYL: 57.33 (+0.09), CBPO: 76.60 (-0.31), RGEN: 25.71 (-0.49), HALO: 15.07 (-0.21), ALIM: 5.23 (-0.05), ACHN: 12.14 (-0.35), GERN: 3.02 (-0.13), DARA: 0.99 (+0.05), SCMP: 15.38 (-0.62), ICPT: 221.37 (+2.30), CDXS: 3.53 (-0.02), PCRX: 114.77 (-1.22), PBYI: 213.01 (+7.05), FOLD: 8.76 (-0.03)
Orexigen's Q4 Results Disappoint, But Contrave Is Gaining Market Share
Kanak Kanti De - at Seeking Alpha - Thu Feb 26, 3:39PM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch
Brian Orelli, The Motley Fool - Motley Fool - Thu Feb 26, 6:02AM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave was nothing to get too excited about. In the fourth quarter, which included 10 weeks of the launch, net sales of the drug were just $6.5 million, which resulted in $1.3 million in...
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena: Belviq Television Ads Resume After 1 Week Hiatus
Spencer Osborne - at Seeking Alpha - Tue Feb 24, 7:11AM CST
OREX: 5.64 (-0.23), ARNA: 4.51 (-0.24)
Orexigen: Contrave Scripts Pass 9,000 - Closing In On Qsymia
Spencer Osborne - at Seeking Alpha - Mon Feb 23, 10:00AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena: Belviq Sales Show Modest Gain - Time To Assess 2015 Expectations?
Spencer Osborne - at Seeking Alpha - Mon Feb 23, 9:33AM CST
OREX: 5.64 (-0.23), NVO: 47.75 (+0.22), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena's Belviq Slows At A Bad Time
Clinically Sound Investor - at Seeking Alpha - Mon Feb 23, 8:57AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus
at The Street - Fri Feb 20, 2:47PM CST
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 0.94 (unch), AMRN: 1.51 (+0.05), HWAY: 22.38 (-0.37), HLS: 43.46 (-0.62), CYBX: 68.50 (+1.90), ESRX: 84.79 (+0.25), ECYT: 5.80 (-0.11), DXCM: 60.74 (-1.22), NSTG: 10.51 (-0.08), SRPT: 13.90 (+0.08), HZNP: 20.53 (+1.46), MDXG: 10.35 (-0.13), DEPO: 21.95 (-0.65), ANIK: 39.92 (-0.04), NKTR: 13.07 (+0.09), KERX: 12.16 (+0.23), ALIM: 5.23 (-0.05), EPZM: 23.52 (-0.08), AEGR: 27.20 (+0.20), MDRX: 12.01 (-0.74), ELGX: 15.77 (+0.09), NUVA: 45.75 (+0.76), HPTX: 29.55 (+1.82), GNMK: 12.71 (-0.19), MDVN: 117.53 (-2.21), HBIO: 5.46 (-0.09), ACAD: 37.97 (+0.19), ST: 53.74 (+0.09), RPTP: 9.27 (-0.37), FMI: 47.76 (-0.58), GMED: 24.28 (-0.78), JAZZ: 170.09 (-5.10), PTCT: 71.33 (-2.13), INFI: 15.20 (-0.84), ARNA: 4.51 (-0.24), EXEL: 2.93 (unch), NEO: 4.54 (+0.13), EXAS: 22.47 (-0.89), ALKS: 70.25 (-0.98), HTWR: 85.23 (-1.15), MNKD: 6.52 (-0.30), IPXL: 40.29 (-0.41), SQNM: 3.50 (-0.02), HALO: 15.07 (-0.21), ISIS: 68.56 (+1.23), CLVS: 76.46 (-1.43), BIO: 127.18 (+8.18), BIOS: 6.11 (+0.19), PCRX: 114.77 (-1.22)
Orexigen's Contrave Sales Recover - Investors Should Look To Europe
Spencer Osborne - at Seeking Alpha - Wed Feb 18, 11:02AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena's Belviq Scripts Spike - Maintaining This Trajectory Important
Spencer Osborne - at Seeking Alpha - Wed Feb 18, 8:22AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference
PR Newswire - Wed Feb 18, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 2015 RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The New York Palace Hotel in New York City.
ARNA: 4.51 (-0.24)
Vivus' Qsymia Experiencing Both Prescription Growth And Market Share Erosion
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:03PM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Orexigen's Contrave Resumes Solid Growth Rate
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:45AM CST
OREX: 5.64 (-0.23), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Arena's Belviq Hits New High Prescription Mark, But Needs Similar Future Growth
Clinically Sound Investor - at Seeking Alpha - Tue Feb 17, 7:42AM CST
ARNA: 4.51 (-0.24)
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 102.51 (-0.29), OREX: 5.64 (-0.23), ECYT: 5.80 (-0.11), NVO: 47.75 (+0.22), MRK: 58.54 (-0.42), VVUS: 2.61 (-0.08), ARNA: 4.51 (-0.24)
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.64 (-0.23), VRTX: 119.43 (-0.54), NVO: 47.75 (+0.22), VVUS: 2.61 (-0.08), QSII: 17.38 (-0.04), MDRX: 12.01 (-0.74), ARNA: 4.51 (-0.24)
(0)
(0)Scroll down for more posts ▼